Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunological response study of three sublingual grass pollen immunotherapy formulations
2006-002123-17Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Jan 2012
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of alutard phleum pratense and phleum pratense allergen extract in seasonal allergic rhinitis (SAR) and allergic rhinoconjunctivitis (ARC) (3 arms), sponsored by Imperial College London. Primary endpoints: Immunological response after 8 weeks of treatment and Safety by daily adverse event recording. Started Jan 2012; status: completed.
02
Drugs
alutard phleum pratensephleum pratense allergen extract
03
Conditions
seasonal allergic rhinitis (SAR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2006-002123-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002123-17.